Table 3.
Casirivimab and imdevimab immunogenicity by anti-drug antibody status.
| ADA Status and Category | Placebo n (%) | CAS+IMD 1200 mg SC Q4W n (%) | Overall n (%) |
|---|---|---|---|
| Casirivimab immunogenicity | |||
| ADA analysis set | 237 (100) | 717 (100) | 954 (100) |
| Negative | 228 (96.2) | 687 (95.8) | 915 (95.9) |
| Pre-existing immunoreactivity | 8 (3.4) | 22 (3.1) | 30 (3.1) |
| Treatment-boosted response | 0 | 0 | 0 |
| Treatment-emergent response | 1 (0.4) | 8 (1.1) | 9 (0.9) |
| Imdevimab immunogenicity | |||
| ADA analysis set | 237 (100) | 717 (100) | 954 (100) |
| Negative | 221 (93.2) | 653 (91.1) | 874 (91.6) |
| Pre-existing immunoreactivity | 9 (3.8) | 28 (3.9) | 37 (3.9) |
| Treatment-boosted response | 0 | 0 | 0 |
| Treatment-emergent response | 7 (3.0) | 36 (5.0) | 43 (4.5) |
ADA, anti-drug antibody; Q4W, every 4 weeks; SC, subcutaneous.
n = number of participants contributing to each category.